Vaccines to prevent lung infections caused by non-tuberculous mycobacteria in at-risk individuals
Official title: Targeted vaccines against pulmonary NTM infections in vulnerable populations
Funded at Seattle Children's Hospital · NIH-11048514 · Data updated 2026-11-12
This study is testing new vaccines to help protect people at risk of serious lung infections caused by non-tuberculous mycobacteria, with the goal of boosting their immune response and reducing the need for long-term medications.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | December 20, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $950,092 |
| NIH project number | 1R01AI183642-01A1 |
| Project ID | NIH-11048514 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include older adults and individuals with weakened immune systems who are at higher risk for NTM infections.
✕Less likely to help
Patients who are not at risk for NTM infections or those who do not have underlying health conditions may not benefit from this research.
What this research studies
This research focuses on developing targeted vaccines to combat non-tuberculous mycobacterial (NTM) infections, which are increasingly prevalent and can lead to severe lung disease. The approach involves creating two types of vaccines: an adjuvated subunit vaccine and a novel RNA-based vaccine, both designed to enhance immunity in vulnerable populations. The study will evaluate the effectiveness of these vaccines using advanced laboratory techniques and mouse models to ensure they provide a robust immune response against NTM infections. By improving immunity and potentially reducing the need for lengthy drug treatments, this research aims to offer a new preventive strategy for at-risk individuals.
Why it matters
Potential benefit: If successful, this research could lead to effective vaccines that significantly reduce the incidence of NTM lung disease and improve treatment outcomes for patients.
How similar studies have gone: While the approach of developing vaccines for NTM infections is innovative, similar vaccine strategies have shown promise in other infectious diseases, indicating potential for success.
Where this research is happening
-
Seattle Children's Hospital
Seattle, United States Active
Researchers
- Principal investigator: Coler, Rhea N — Seattle Children's Hospital
- Study coordinator: Coler, Rhea N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.